Elevated LINC00909 Promotes Tumor Progression of Ovarian Cancer via Regulating the miR-23b-3p/MRC2 Axis

Table 1

Characteristics of patients with ovarian cancers.

Characteristics	Number ()
Age	Median (67 years) with range of 21-90 years
FIGO stage
I	31 (14.3%)
II	33 (15.2%)
III	80 (36.9%)
IV	71 (32.7%)
ECOG
0	35 (16.1%)
I	54 (24.9%)
II	51 (23.5%)
III	69 (31.8%)
IV	7 (3.2%)
Histologic subtypes
Serous	170 (78.3%)
Endometriods	25 (11.5%)
Clear cell	21 (9.7%)
Recurrence
PFS	Median (479 days) with range of 53-1362 days
NO relapse	76 (35%)
Relapse	140 (64.5%)
Survival
OS	Median (618 days) with range of 102-1774 days
Alive	172 (79.3%)
Dead	45 (20.7%)

FIGO stage (I-IV), FIGO Committee on Gynecologic Oncology 2009 I: tumor confined to ovaries or fallopian tube(s); II: tumor involves one or both ovaries or fallopian tubes with pelvic extension (below pelvic brim) or peritoneal cancer (Tp); III: tumor involves one or both ovaries, or fallopian tubes, or primary peritoneal cancer, with cytologically or histologically confirmed spread to the peritoneum outside the pelvis and/or metastasis to the retroperitoneal lymph nodes; IV: distant metastasis excluding peritoneal metastases. ECOG (0-IV), Eastern Cooperative Oncology Group score 0: fully active, able to carry on all predisease performance without restriction; I: restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light housework and office work; II: ambulatory and capable of all self-care but unable to carry out any work activities; up and about more than 50% of waking hours; III: capable of only limited self-care, confined to bed or chair more than 50% of waking hours; IV: completely disabled; cannot carry out any self-care; totally confined to bed or chair; V: dead. PFS: progression-free survival; OV: overall survival.